Observational studyScientific reports2022
Different clinical characteristics and impact of carbapenem-resistance on outcomes between Acinetobacter baumannii and Pseudomonas aeruginosa bacteraemia: a prospective observational study.
Observational study in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Landscape of resistance to ceftolozane/tazobactam and ceftazidime/avibactam in strains of Pseudomonas aeruginosa: a genomic approach in strains without selection pressure in a tertiary-care paediatric hospital in Mexico.BMC infectious diseases · 2026Article
- Phenotypic and Genotypic Characterization of Carbapenem-ResistantInternational journal of microbiology · 2026Article
- In Vitro Activity of Novel β-Lactam/β-Lactamase Inhibitors Against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Evaluation of the quickmic system in the rapid diagnosis of Gram-negative bacilli bacteremia.Microbiology spectrum · 2024Article
- The Microbiological Characteristics ofOpen forum infectious diseases · 2024Article
- Limited impact of bacterial virulence on early mortality risk factors in Acinetobacter baumannii bacteremia observed in a Galleria mellonella model.Scientific reports · 2024Article
- Optimizing Treatment for Carbapenem-ResistantInfection & chemotherapy · 2024Review
- Article
- Clinical Characteristics and Associated Factors for Mortality in Patients with Carbapenem-ResistantMicroorganisms · 2023Article
- Atom Economical QPCs: Phenyl-Free Biscationic Quaternary Phosphonium Compounds as Potent Disinfectants.ACS infectious diseases · 2023Article
- Antimicrobial Therapy Duration for Bloodstream Infections Caused byAntibiotics (Basel, Switzerland) · 2023Article
- Novel evidence on sepsis-inducing pathogens: from laboratory to bedside.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the differences in clinical characteristics and impact of carbapenem resistance (CR) on outcomes between Acinetobacter baumannii (Ab) and Pseudomonas aeruginosa (Pa) bacteraemia. We prospectively identified all patients with Ab and Pa bacteraemia in 10 hospitals over 1 year. Treatment failure was defined as all-cause 30-day mortality, persistent bacteraemia, or recurrent bacteraemia within 30 days. We included 304 Ab and 241 Pa bacteraemia cases. CR was detected in 216 patients (71%) with Ab bacteraemia and 55 patients (23%) with Pa bacteraemia. Treatment failure was significantly higher in CR-Ab than in CR-Pa (60.6% vs. 34.5%, P = 0.001). In Ab, severe sepsis or septic shock and high Pitt bacteraemia score were independent risk factors for treatment failure in the inappropriate empirical antibiotics group. In Pa, hospital-acquired infection and high Pitt bacteraemia score were independent risk factors for treatment failure in both groups. CR was an independent risk factor in Ab for treatment failure in both groups, but not in Pa bacteraemia. We demonstrated significant differences in clinical characteristics and impact of CR on clinical outcomes between Ab and Pa bacteraemia, suggesting that different treatment approaches may be needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.